Oct 11th 2012 - Edison Investment Research today published a report on Adventrx Pharmaceuticals entitled "ANX-188 Poised For Pivotal Role". In summary, the report says:
Adventrx is on the verge of initiating its all-important pivotal Phase III study of ANX-188, a product that has the potential to become the standard of care to treat severely painful ‘crisis’ episodes in patients with sickle cell disease. The key requirements are now in place – manufacturing and CRO contracts have been secured – and assuming the FDA has no objections to the trial design, the study should start by end 2012. Advancing ANX-188 into Phase III, and clarity on the study design, represents a significant milestone and potential catalyst that could lead to a re-rating.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »